Harnessing AI to Design Antibodies Against Complex Targets in Autoimmune Diseases and Oncology

Biolojic Design computationally designs and programs novel antibodies against complex therapeutic targets, maximizing the full potential of well-studied biological pathways.

Using 3D modeling and machine learning, the company is able to characterize antibody binding sites with a high degree of precision and make amino acid level changes to dramatically improve their functionality and precision. Biolojic’s AI-designed antibodies provide a precise molecular effect, in the desired micro-environment, at the right time, leading to greater efficacy and lower toxicity, while maintaining impeccable developability, half-life, stability and safety of human antibodies.

Targeting well-understood, validated biological pathways, beginning with autoimmune diseases and immuno-oncology, Biolojic's smart antibodies affect these pathways more precisely and can succeed where traditional drugs have failed.